Clinical data
ATC code None
Pharmacokinetic data
Protein binding ~89%
Biological half-life 2.5–5.5 hours
CAS Number 452-35-7 YesY
PubChem (CID) 3295
DrugBank DB00311 YesY
ChemSpider 3179 YesY
UNII Z52H4811WX YesY
KEGG D02441 YesY
ChEBI CHEBI:101096 YesY
ECHA InfoCard 100.006.546
Chemical and physical data
Formula C9H10N2O3S2
Molar mass 258.319 g/mol
3D model (Jmol) Interactive image

Ethoxzolamide (alternatively known as ethoxyzolamide) is a sulfonamide medication that functions as a carbonic anhydrase inhibitor. It is used in the treatment of glaucoma and duodenal ulcers, and as a diuretic. It may also be used in the treatment of some forms of epilepsy.


Ethoxzolamide, a sulfonamide, inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate. It also decreases carbonic anhydrase in the CNS, increasing the seizure threshold. This reduction in carbonic anhydrase also reduces the intraocular pressure in the eye by decreasing aqueous humor.

Mechanism of action

Ethoxzolamide binds and inhibits carbonic anhydrase I. Carbonic anhydrase plays an essential role in facilitating the transport of carbon dioxide and protons in the intracellular space, across biological membranes and in the layers of the extracellular space. The inhibition of this enzyme effects the balance of applicable membrane equilibrium systems.


Ethoxzolamide synthesis: GB 795174 ; J. Korman, U.S. Patent 2,868,800 (1958, 1959 both to Upjohn).

See also

This article is issued from Wikipedia - version of the 9/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.